|
摘要：
|
|
摘要：近年来，免疫治疗已成为肿瘤领域的一项重大突破。免疫检查点抑制剂
（immune checkpoint inhibitors，ICIs）通过阻断免疫检查点的抑制性免疫调节作用
活化T细胞，增强机体抗肿瘤免疫应答。随着ICIs的广泛应用，免疫相关不良事件
（immune-related adverse events，irAEs）日益引起各科临床医师的重视。其中，ICIs诱
发的免疫相关肝毒性（immune-mediated hepatotoxicity，IMH）甚至可导致肝衰竭或死
亡，其发生率有逐渐升高趋势。本文针对IMH的发生、可能机制、病理以及诊治等进
行综述。
|
|
Abstract: In recent years, immunotherapy has become a major breakthrough in the field of
oncology. Immune checkpoint inhibitors (ICIs) can activate T cells and enhance the antitumor immune response by blocking the inhibitory immune-regulatory effects. With the wide
application of ICIs, immune-related adverse events (irAEs) are increasingly concerned by
multidisciplinary clinicians. The incidence of ICIs induced immune-mediated hepatotoxicity
(IMH) which could lead to liver failure or death has been increasing. This article reviews the
occurrence, possible mechanism, pathology, diagnosis and treatment of IMH.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|